---
title: 'Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients
  with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world
  conditions in Germany: the non-interventional study coveNIS'
date: '2023-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37962220/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231114170859&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'Cobimetinib/vemurafenib combination therapy is approved for treatment
  of adults with unresectable or metastatic BRAF V600 mutated malignant melanoma (mM).
  The non-interventional post-authorisation safety study coveNIS collected real-world
  data on cobimetinib/vemurafenib treatment focussing on overall survival (OS), safety
  and utilization. MM patients with brain metastases are usually excluded from clinical
  studies. coveNIS observed 2 cohorts: mM patients without (Cohort A) and with ...'
disable_comments: true
---
Cobimetinib/vemurafenib combination therapy is approved for treatment of adults with unresectable or metastatic BRAF V600 mutated malignant melanoma (mM). The non-interventional post-authorisation safety study coveNIS collected real-world data on cobimetinib/vemurafenib treatment focussing on overall survival (OS), safety and utilization. MM patients with brain metastases are usually excluded from clinical studies. coveNIS observed 2 cohorts: mM patients without (Cohort A) and with ...